Oral versus inhaled antibiotics for non‐cystic fibrosis bronchiectasis
Referencias
Additional references
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics ‐ part 1: biological mechanisms. Respiration 2011;81(1):67‐74.
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics ‐ part 2: advantages and disadvantages of long‐term, low‐dose macrolide therapy. Respiration 2011b;81(1):75‐87.
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. Journal of the American Medical Association 2013;309(12):1251‐9.
Joint Formulary Committee. British National Formulary. www.medicinescomplete.com/mc/?utm_source=bnforg&utm_medium=homepage&utm_campaign=medicinescomplete (accessed 13 October 2016).
Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non‐cystic fibrosis bronchiectasis: a systematic review. European Respiratory Journal 2014;44(2):382‐93. [DOI: 10.1183/09031936.00018414]
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;186(7):657‐65.
Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. European Respiratory Journal 2016;2(1):00081‐2015. [DOI: 10.1183/23120541.00081‐2015]
Chang AB, Bell SC, Byrnes CA, Grimwood K, HolmesP, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Medical Journal of Australia 2010;193(6):356‐65.
Dudley MN, Loutit J, Griffith DC. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Current Opinion in Biotechnology 2008;19(6):637‐43.
Gibson GJ, Loddenkemper R, Lundback Bo, Sibille Y (eds). Bronchiectasis. European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013. [http://www.erswhitebook.org/]
Felix Lambert M, Grundy S, Milan Stephen J, Armstrong R, Harrison H, Lynes D, et al. Dual antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012514]
Felix LM, Chalmers JD, Spencer S, Donovan T, Milan SJ, Mathioudakis AG. Continuous versus intermittent antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews.
Geller DE. Aerosol antibiotics in cystic fibrosis. Respiratory Care 2009;54(5):658‐70.
Goeminne P, Dupont L. Non‐cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgraduate Medical Journal 2010;86(1018):493‐501.
Goeminne PC, Vandooren J, Moelants EA, Decraene A, Rabaey E, Pauwels A, et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: a case‐control analysis. Respirology 2014;19(2):203‐10.
Pieter G, De Soyza A. Bronchiectasis: how to be an orphan with many parents?. European Respiratory Journal 2016;47(1):10‐3.
GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 1 March 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Annals of Thoracic Medicine 2011;6(3):131‐6.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone M, Smith BJ. Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD001392.pub3]
Kaehne A, Milan SJ, Felix LM, Spencer S, Sheridan E, Marsden PA. Head to head trials of antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews2017.
Kelly C, Evans David J, Chalmers James D, Crossingham I, Spencer S, Relph N, et al. Macrolide antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD012406]
Kolbe J, Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology 1996;1(4):221‐5.
Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non‐cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Annals of the American Thoracic Society 2015;12(12):1764‐70.
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non‐CF Guideline Group. British Thoracic Society guideline for non‐CF bronchiectasis. Thorax 2010;65(Suppl 1):i1‐58.
Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal 2016;47(1):186‐93.
Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society 2014;11(3):425‐34.
Restrepo MI, Keyt H, Reyes LF. Aerolized antibiotics. Respiratory Care 2015;60(6):762‐1; discussion 771‐3.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine 2010;104:981‐5.
Rubin BK. Aerosolized antibiotics for noncystic fibrosis bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2008;21(1):71‐6.
Ryan G, Singh M, Dwan K. Inhaled antibiotics for long‐term therapy in cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD001021.pub2]
Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis‐associated hospitalizations in the United States, 1993‐2006. Chest 2010;138:944‐9.
Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000‐2007. Chest 2012;142(2):432‐9.
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomised controlled trial. JAMA 2013;309(12):1260‐7.
Welsh EJ, Evans DJ, Fowler SJ, Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD010337.pub2]
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205‐9.
Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, et al. Challenges in managing pseudomonas aeruginosa in non‐cystic fibrosis bronchiectasis. Respiratory Medicine 20165;117:179‐89.
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet 2012;380(9842):660‐7.
Yang JW, Fan LC, Lu HW, Miao XY, Mao B, Xu JF. Efficacy and safety of long‐term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta‐analysis. Clinical Respiratory Journal 2015 Jan 26 [Epub ahead of print]. [DOI: 10.1111/crj.12278]
